{"url_path":"/sec/iron/8-k/2026-06-24/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1816736/0001193125-26-281096-index.html","accession_number":"0001193125-26-281096","cik":"0001816736","ticker":"IRON","issuer_name":"Disc Medicine, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1816736/0001193125-26-281096-index.html","primary_entity_key":"0001816736","primary_entity_name":"Disc Medicine, Inc."},"word_count":407,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 18, 2026, Disc Medicine, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company’s Definitive Proxy Statement on Schedule 14A, which was filed with the Securities and Exchange Commission on April 28, 2026 (the \"Proxy Statement\"). The final voting results are set forth below.\n\nProposal 1 - Election of Class III Director Nominees\n\nThe stockholders of the Company elected Donald Nicholson, Ph.D., John Quisel, J.D., Ph.D., and William White, M.P.P., J.D. as Class III directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. The results of the stockholders’ vote with respect to the election of the Class III directors were as follows:\n\n \n\nName\n\n \n\nVotes For\n\n \n\nVotes Withheld\n\n \n\nBroker Non-Votes\n\nDonald Nicholson, Ph.D.\n\n \n\n28,559,799\n\n \n\n5,347,450\n\n \n\n2,011,469\n\nJohn Quisel, J.D., Ph.D.\n\n \n\n33,433,078\n\n \n\n474,171\n\n \n\n2,011,469\n\nWilliam White, M.P.P., J.D.\n\n \n\n33,355,406\n\n \n\n551,843\n\n \n\n2,011,469\n\n \n\nProposal 2 - Approval, on a Non-Binding, Advisory Basis, of the Compensation Paid to the Company's Named Executive Officers\n\nThe stockholders of the Company approved, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers as described in the Proxy Statement. The results of the stockholders’ vote with respect to the approval, on a non-binding, advisory basis, of the compensation paid to the Company's named executive officers were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n33,528,449\n\n \n\n368,970\n\n \n\n9,830\n\n \n\n2,011,469\n\nProposal 3 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm\n\nThe stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstain\n\n35,908,900\n\n \n\n1,298\n\n \n\n8,520\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nDISC MEDICINE, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 24, 2026\n\nBy:\n\n/s. John Quisel, J.D., Ph.D\n\n \n\n \n\n \n\nName: John Quisel, J.D., Ph.D.\nTitle: President and Chief Executive Officer"}